Skip to main content

Table 1 Genotypic resistance mutations before switching to a double-boosted protease inhibitors regimen

From: Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population

 

NNRTI

PI

Resistant Drugs

Patient

98 (G)

103 (R/N)

108 (I)

135 (L/I/V)

283 (I)

  

P1

G

  

L

 

63 P, 71 V, 77 wt/I, 93 L

NVP L-lR

P2

 

N

I 

N

I

10 V, 35 D

EFV and NVP L-lR

P3

    

 wt/I

77I

none

P4

     

63 P, 93 L

none

P5

 

V

 

V

 

35 D, 60 E, 63 P

none

P6

     

No mutations

none

P7

 

R

 

T

 

10 V, 13 wt/V, 63 P, 77 I

none

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us